Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gallium Ga-68 Gozetotide

FDA-approved product (solution, intravenous), marketed as Gallium Ga 68 Gozetotide, Gozellix, Illuccix and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gallium Ga-68 Gozetotide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neuroimaging measurement

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gallium Ga-68 Gozetotide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gallium Ga-68 Gozetotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

    NCT07674771 · start 2026-10

    Registered record
    Registry ID
    NCT07674771
    Conditions
    Prostate Cancer; Castration Sensitive Prostate Cancer; Metastatic Prostate Cancer; Adaptive Radiotherapy
    Interventions
    Drug: 68-Ga PSMA11; Adaptive stereotactic ablative radiotherapy (SABR); 68Ga-PSMA-11; Adaptive stereotactive ablative radiotherapy (SABR)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2029-06-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Castration Sensitive Prostate Cancer; Metastatic Prostate Cancer; Adaptive Radiotherapy
    InterventionDrug: 68-Ga PSMA11; Adaptive stereotactic ablative radiotherapy (SABR); 68Ga-PSMA-11; Adaptive stereotactive ablative radiotherapy (SABR)
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

    NCT07150715 · start 2025-12-12

    Registered record
    Registry ID
    NCT07150715
    Conditions
    Oligometastatic Prostate Adenocarcinoma; Recurrent Prostate Adenocarcinoma
    Interventions
    Actinium Ac 225 Vipivotide Tetraxetan; Biospecimen Collection; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; PSMA PET-CT Scan; Stereotactic Body Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-12
    Completion
    2031-10-31
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOligometastatic Prostate Adenocarcinoma; Recurrent Prostate Adenocarcinoma
    InterventionActinium Ac 225 Vipivotide Tetraxetan; Biospecimen Collection; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan +2 more
    PhasePhase 2
    Registry statusRecruiting

  • The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture

    NCT06901492 · start 2025-06-01

    Registered record
    Registry ID
    NCT06901492
    Conditions
    PSMA PET/CT; Prostate Cancer; MpMRI
    Interventions
    Prostate biopsy guided by PSMA PET/CT; Prostate biopsy guided by mpMRI/US; Systematic prostate biopsy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-06-01
    Completion
    2028-06-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPSMA PET/CT; Prostate Cancer; MpMRI
    InterventionProstate biopsy guided by PSMA PET/CT; Prostate biopsy guided by mpMRI/US; Systematic prostate biopsy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy

    NCT07829068 · start 2025-05-30

    Registered record
    Registry ID
    NCT07829068
    Conditions
    Prostate Cancer; PSMA PET/CT; Margin Assessment
    Interventions
    study-specific administration of 68Ga-PSMA-11 followed by ex vivo PET/CT imaging of the prostatectomy specimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2025-05-30
    Completion
    2027-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; PSMA PET/CT; Margin Assessment
    Interventionstudy-specific administration of 68Ga-PSMA-11 followed by ex vivo PET/CT imaging of the prostatectomy specimen
    PhaseNot applicable
    Registry statusActive not recruiting

  • Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

    NCT06450548 · start 2025-03-05

    Registered record
    Registry ID
    NCT06450548
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Parametric acquisition
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-03-05
    Completion
    2028-03-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionParametric acquisition
    PhaseNot applicable
    Registry statusRecruiting

  • Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

    NCT06655064 · start 2025-01-30

    Registered record
    Registry ID
    NCT06655064
    Conditions
    Prostate Cancer (Adenocarcinoma)
    Interventions
    None- Observational
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2025-01-30
    Completion
    2025-06-17
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Adenocarcinoma)
    InterventionNone- Observational
    PhaseNot recorded
    Registry statusTerminated

  • Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

    NCT06907641 · start 2024-11-21

    Registered record
    Registry ID
    NCT06907641
    Conditions
    Prostate Cancer (Post Prostatectomy)
    Interventions
    64Cu-SAR-bisPSMA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-11-21
    Completion
    2025-09-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Post Prostatectomy)
    Intervention64Cu-SAR-bisPSMA
    PhasePhase 2
    Registry statusCompleted

  • European Registry of Next Generation Imaging in Advanced Prostate Cancer

    NCT06866782 · start 2024-09-17

    Registered record
    Registry ID
    NCT06866782
    Conditions
    Prostate Cancer; Advanced Prostate Cancer; Metastatic Prostate Cancer (mPC)
    Interventions
    Imaging
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-09-17
    Completion
    2026-12-23
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Advanced Prostate Cancer; Metastatic Prostate Cancer (mPC)
    InterventionImaging
    PhaseNot recorded
    Registry statusRecruiting

  • An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

    NCT06521775 · start 2024-08-12

    Registered record
    Registry ID
    NCT06521775
    Conditions
    Metastatic Adenoid Cystic Carcinoma
    Interventions
    Computed Tomography; Electronic Health Record Review; Ga-68 PSMA-11; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-08-12
    Completion
    2025-08-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Adenoid Cystic Carcinoma
    InterventionComputed Tomography; Electronic Health Record Review; Ga-68 PSMA-11; Positron Emission Tomography
    PhasePhase 2
    Registry statusCompleted

  • Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

    NCT06039371 · start 2024-05-21

    Registered record
    Registry ID
    NCT06039371
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Scan; Carboplatin; Computed Tomography; Etoposide; Quality-of-Life Assessment; Questionnaire Administration; Testosterone Cypionate; Radioconjugate; Dual X-ray Absorptiometry; Gallium Ga 68-PSMA-617; Positron Emission Tomography; Single Photon Emission Computed Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-21
    Completion
    2028-11-01
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Scan; Carboplatin +10 more
    PhasePhase 2
    Registry statusRecruiting

  • Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

    NCT06004661 · start 2024-04-04

    Registered record
    Registry ID
    NCT06004661
    Conditions
    Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Interventions
    AAA617; 68Ga-PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-04-04
    Completion
    2026-12-14
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer (mCRPC)
    InterventionAAA617; 68Ga-PSMA-11
    PhasePhase 2
    Registry statusActive not recruiting

  • PSMA PET Response Guided SabR in High Risk Pca

    NCT06044857 · start 2024-03-07

    Registered record
    Registry ID
    NCT06044857
    Conditions
    Prostate Adenocarcinoma
    Interventions
    68-Ga PSMA11
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-03-07
    Completion
    2026-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    Intervention68-Ga PSMA11
    PhasePhase 1
    Registry statusRecruiting

  • Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas

    NCT06241391 · start 2024-02

    Registered record
    Registry ID
    NCT06241391
    Conditions
    Glioma; Astrocytoma; Anaplastic Astrocytoma; Oligodendroglioma; Glioblastoma Multiforme
    Interventions
    PSMA PET-CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-02
    Completion
    2025-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma; Astrocytoma; Anaplastic Astrocytoma; Oligodendroglioma +1 more
    InterventionPSMA PET-CT
    PhaseNot applicable
    Registry statusUnknown

  • Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging

    NCT07324733 · start 2023-10-01

    Registered record
    Registry ID
    NCT07324733
    Conditions
    Primary Sjögren Syndrome; PET
    Interventions
    ⁶⁸Ga-PSMA PET/CT; ⁶⁸Ga-FAPI PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-10-01
    Completion
    2026-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Sjögren Syndrome; PET
    Intervention⁶⁸Ga-PSMA PET/CT; ⁶⁸Ga-FAPI PET/CT
    PhaseNot applicable
    Registry statusRecruiting

  • Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

    NCT05955677 · start 2023-07-10

    Registered record
    Registry ID
    NCT05955677
    Conditions
    Prostate Cancer; PET/CT
    Interventions
    [68Ga]Ga-PSMA-D5; [68Ga]Ga-PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2023-07-10
    Completion
    2024-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; PET/CT
    Intervention[68Ga]Ga-PSMA-D5; [68Ga]Ga-PSMA-11
    PhaseEarly phase 1
    Registry statusUnknown